All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 30, 2022
Home » Blogs » BioWorld MedTech Perspectives » I've got 99 problems but a CT scan isn't one of 'em

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / Imaging

I've got 99 problems but a CT scan isn't one of 'em

June 28, 2013
By Omar Ford
No Comments

CTAs a proud father of a two-year-old little girl, it's always stories the stories about children that grab my attention the most. Take for instance, a recent one that I wrote, discussing the risk of radiation-induced solid cancers in older children. The story comes from a study published in the journal JAMA Pediatrics and possible appendicitis was cited as a leading cause of abdominal/pelvic CT usage.

The first question I asked myself, one that I had never asked before... was if I should be overly concerned if my daughter needs a CT scan. The good news is, one med-tech company in particular is focused on obtaining FDA clearance for an assay that could help reduce the number of CT scans in children who are thought to suffer from appendicitis, if given the green light. Venaxis (Castle Rock, Colorado) reported that it has developed the APPY1 Test, a rapid, protein biomarker-based assay for identifying patients at low risk for appendicitis.

While it still has to clear a few hurdles before this test reaches the market, I'm pleased that such an option will be on the table, especially after seeing some of the statistics from the JAMA Pediatrics article.

In the study researchers measured the rate of CT scan use (from 1996 to 2010) and the dose of ionizing radiation (for CT scans performed between 2001 and 2011) in children younger than 15 years of age, and estimated the lifetime attributable risks of certain cancers. The projected lifetime attributable risk of developing solid cancers was higher for patients who underwent CT scans of the abdomen/pelvis or spine than for patients who underwent other types of CT scans. The risk was highest for younger patients and for girls (did I mention I have a daughter?), with a radiation-induced solid cancer projected to result from every 300 to 390 abdomen/pelvis scans.

Currently, the company is undergoing a pivotal trial for the APPY1 test and hopefully approval will be right around the corner and this dad can eliminate a CT scan as a potential worry. I'm sure there will be plenty of other worries to take its place.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 29, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for June 29.
  • Enhertu.png

    Swing low, sweet Enhertu: Astrazeneca, Daiichi ASCO data carry HER2 message home

    BioWorld
    The “showdown” at the American Society of Clinical Oncology (ASCO) meeting foreseen by one analyst between breast cancer drugs from Gilead Sciences Inc. and...
  • Novavax-COVID-19-vaccine-vial

    Novavax vaccine shows its chops

    BioWorld
    Given that Novavax Inc.’s COVID-19 vaccine will be a latecomer to the U.S. scene if it gets FDA authorization, it’s been cast in a supporting role to the lead...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing